The #PrEP4All campaign made the call for affordable pre-exposure prophylaxis a national news story.
Activists and doctors say they're ready to go further if Gilead won't agree to -- or the U.S. government won't force -- a price reduction to make PrEP accessible to more Americans who need it.
Advocates say the price is a step in the right direction. But does it go far enough?
But a survey reveals that about a third of black and Latino gay men would be willing to pay more than $50 per month for a prescription.
In a debate during a plenary session, Michael Saag, M.D., argued for more activism to make PrEP accessible to people who need it.
Drug pricing expert Tim Horn helps us make sense of the administration's future plans for the Medicare Part D and 340B programs.
Despite the tremendous success of the program -- or perhaps because of it -- and courtesy of a substantial lobbying push from the Pharmaceutical Research and Manufacturers of America (PhRMA), the 340B program has found itself under close scrutiny by ...
A program that lowers drug costs for Ryan White clinics, community health centers, family planning clinics, and hospitals serving low-income patients is under attack by Republicans in Congress and the Trump Administration.
Big Pharma money can beef up public health efforts. But it can also distract from unchecked drug pricing -- and from government negligence.
Reining in prescription drug prices isn't so much a potential benefit of universal health care, but rather a factor in its affordability and success.